10
February / March 2012
Chromatographic Characterisation and
Purification Techniques for BioPharm Focusing on Monoclonal Antibody Derived Drugs
Glaxosmithkline Medicines Research Centre Stevenage Herts UK, 14 & 15 March 2012
Monoclonal antibodies are a very high growth segment in the biologically active molecules armoury of the Pharmaceutical industry. Annual sales are expected to exceed £35 Billion in the next four years. 23 full-size monoclonal antibodies and 3 monoclonal antibody fragments have been launched, with many reaching blockbuster status. An overview of the importance and value of large biomolecules to the pharmaceutical industry is evident from the data in the table below:
New emerging therapeutics:
The characterisation and purification of these molecules is currently one of the biggest scientific and technical challenges facing the pharmaceutical industry.
This symposium will focus on solutions to these problems and discuss the unique issues presented by structurally complex, large molecular weight, biologically active molecules. An exhibition of tools necessary to address these problems will augment the lecture presentations.
Experts from within the pharmaceutical industry and from instrumentation and consumable suppliers will present their latest innovations.
The two day symposium will be held at the GSK R&D site at Stevenage and will facilitate delegate and exhibitor access to GSK’s in-house scientists.
The afternoon of Day 2 will feature two specialist workshops run by expert analysts from within GSK and from companies with proven solutions to the many analytical and preparative challenges incurred in characterising complex biomolecules. The aim will be to inform you with as much freedom of discussion as possible to ensure your questions and problems are addressed professionally with state of the art knowledge.
In addition to chromatographic and electrophoretic separation science techniques our presenters will include mass spectrometry, NMR and structural methods to enable a more complete characterisation of these complex biomolecules.
In addition to the GSK scientists’ lectures, presentations to note will be:
Analytical Development of Biopharmaceuticals and Assessment of Modification sites
Alistair D. Kippen, Director, Analytical Biochemistry, Medimmune, Cambridge
“A new approach for mAb aggregate detection – HIC with nonporous resin”
Judith Vajda, (Tosoh Bioscience)
“High Resolution methods for speeding up Bio-Therapeutic protein analysis”
Ken Cook (THERMOFISHER DIONEX)
“Aeris: Core-Shell Technology for Proteins and Peptides” James Rudge (PHENOMENEX)
“Advanced Analytical Workflows for Characterisation of Biological Entities – from intact mAbs to N-Glycans” Ashley Sage (AGILENT)
"Improved Method Development Workflows for Ion Exchange and Size Exclusion Chromatography of Biotherapeutics"
Patrick Boyce (WATERS)
"Identification and characterisation of proteins" Achim Treumann (NEPAF the North East Proteome Analysis Facility)
Possible title: “Envoy” a product for protein disaggregation
Heikki Lanckreit, Founder of Expedeon Protein Solutions Ltd, Cambridgeshire
Porous Graphitic Carbon vs Strong Cation Exchange: Which is best in a 2D proteomics workflow? Joanna Freeke (Thermofisher)
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60
